Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer

Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases

USFDA inspection at Biocon Biologics' manufacturing facility in Johor, Malaysia

Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site

Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening

Evonik and Shandong Vland Biotech form JV in China with focus on gut health products for animals

Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally